TUEBINGEN, Germany, July 14, 2008 – immatics biotechnologies GmbH today announced that the company has obtained European patent protection for its technology platform XPRESIDENT™. In addition, the company has been granted important U.S. and European patents covering compounds contained in its lead product candidates IMA901 and IMA910.
